ArticlePloS one2026
Suicide adverse events associated with zopiclone and eszopiclone: A pharmacovigilance analysis based on FAERS, JADER and CVARD.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sex-specific pharmacovigilance signals and time-to-onset patterns of drug-related myoclonus and epileptic seizures: a real-world pharmacovigilance analysis.Frontiers in pharmacology · 2026Article
- Zopiclone-associated hallucinations: a case report and database pharmacovigilance study.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSuicide adverse events are a serious concern with zopiclone and eszopiclone. This study assessed the risk of such events by mining data from the FAERS, JADER, and CVARD databases.
methodsThe analysis included reports from Q1 2004 to Q4 2024 for FAERS, April 2004 to December 2024 for JADER, and January 1991 to December 2024 for CVARD. The risk was analyzed using the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Information Component (IC).
resultsA total of 361 reports of suicide adverse events linked to zopiclone and eszopiclone were included (FAERS: 120; JADER: 44; CVARD: 197). These events encompassed completed suicide, suicide attempt, suicidal ideation, suicidal behavior, self-injurious ideation, and intentional self-injury. Suicide attempt was consistently detected as a positive signal by all three methods across all databases and classified as a medium clinical priority.Multivariable logistic regression analysis from FAERS data indicated that males had an independently increased risk of suicide associated with these drugs [OR (95% CI): 14.70 (2.64-274.75), p = 0.012]. Most suicide-related events (60.0%) occurred within 0-180 days after taking medication. based on FAERS data. Survival analysis showed no significant gender difference in time to suicide onset (p = 0.15). The hazard rate remained constant over time (Weibull shape β = 0.80). Death was the outcome in 50.0% of cases following suicide onset. The average reported doses for zopiclone (262.5 mg) and eszopiclone (25.6 mg) significantly exceeded maximum recommended dosages.
conclusionThese findings align with published reports and clinical observations, highlighting the need for further clinical trials to investigate suicide associated with zopiclone and eszopiclone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.